Alpha Cognition Inc.
About Alpha Cognition Inc.
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimers disease, for which there are limited or no treatment options. The Companies current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Companies commercial development program for ZUNVEYL is focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $10.2M
- Net income
- -$20.7M
- Total assets
- $79.7M
- Market cap
- $126.7M
- Gross margin
- 94.1%
- Operating margin
- -221.7%
- Net margin
- -202.2%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $10.2M
- Cost of revenue
- $603.4K
- Gross profit
- $9.6M
- Operating expenses
- $32.9M
- Operating income
- -$22.7M
- Net income
- -$20.7M
- EPS (basic)
- $-1.17
- EPS (diluted)
- $-1.18
Balance sheet
- Total assets
- $79.7M
- Current assets
- $79.0M
- Total liabilities
- $17.2M
- Current liabilities
- $9.1M
- Shareholders’ equity
- $62.5M
Cash flow
- Operating cash flow
- -$20.4M
- Investing cash flow
- -$293.5K
- Financing cash flow
- $38.2M
- Net cash flow
- $17.5M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $126.7M
- EPS (diluted)
- $-1.18
- Shares outstanding
- 21.1M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 9, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $20.7M in FY2025.
- Gross margin of 94.1%, net margin -202.2%.
- Trading 46% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Alpha Cognition Inc..
Write a review
News about Alpha Cognition Inc.
News & sentiment via Polygon.io
